Scemblix (asciminib)

Second-generation and third-generation TKIs further improved outcomes by targeting most imatinib-resistant mutations, with ponatinib-based regimens achieving deep molecular responses and long-term survival in most patients. Concurrently, immunotherapies like blinatumomab and CAR-T cells have enabled potent chemotherapy-free strategies, yielding high molecular response rates and challenging the necessity of allo-HSCT for all patients. Current evidence supports reserving allo-HSCT for high-risk patients, while those with sustained minimal residual disease (MRD) negativity may be cured with TKI and immunotherapy alone. Future progress hinges on optimizing combinations, integrating novel agents like asciminib and venetoclax, and leveraging MRD and genomic profiling for precision medicine.

P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Feb 2026 --> Jul 2026

BCR::ABL1 e6a3 demonstrated enhanced sensitivity to active-state selective inhibitors dasatinib and bosutinib, whereas BCR::ABL1 e6a3/T315I remained resistant. These data show that treatment with asciminib and ponatinib can select for mutations with notably elevated enzymatic activity, effectively targeted by an axitinib-based triple combination. These data highlight the remarkable mutability of the BCR::ABL1 kinase, including through novel isoforms and provides a strong rationale for the clinical assessment of a triple inhibitor combination as a strategy to overcome resistance to dual ponatinib and asciminib therapy.

This led to development of tyrosine kinase inhibitors (TKIs) such as Imatinib, Nilotinib, and Ponatinib. Asciminib does not appear to induce a prothrombotic or proinflammatory state under the conditions studied, which may be advantageous for CML patients. However, the observed increase in thrombin generation over time suggests a potential effect on secondary haemostasis that warrants further investigation in controlled studies.

P1/2, N=14, Not yet recruiting, Novartis Pharma AG

Its greatest clinical value appears to lie in rational combination regimens, maintenance strategies, and bridging to definitive therapies rather than single-agent salvage. Emerging structural biomarkers and ongoing clinical trials are expected to further refine patient selection, sequencing, and optimal integration of asciminib, particularly in CNS-involved disease and post-CAR-T cell relapse.

P2, N=50, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P=N/A, N=380, Not yet recruiting, Novartis Pharmaceuticals

Several clinically relevant agents, including dasatinib, ponatinib, and asciminib, incorporate such heterocyclic frameworks, highlighting their therapeutic significance. This review explores the chemical diversity, molecular interactions, and therapeutic potential of five-membered heterocyclic compounds in CML. Overall, these scaffolds represent promising candidates for developing more effective and less toxic treatment strategies, improving long-term patient outcomes.

P2, N=45, Not yet recruiting, University Health Network, Toronto

P=N/A, N=600, Recruiting, Novartis Pharmaceuticals | N=100 --> 600 | Trial completion date: Jul 2025 --> Jun 2030 | Trial primary completion date: Jul 2025 --> Jun 2030